{"id":"lanthanum-carbonate-chewable-tablet","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"10-20","effect":"Constipation"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lanthanum is a rare earth element that acts as a phosphate binder in the GI tract. It dissociates to release lanthanum ions, which form highly insoluble lanthanum phosphate complexes with dietary phosphate. These complexes cannot be absorbed and are excreted in stool, effectively reducing the bioavailability of phosphate and lowering serum phosphate concentrations in patients with hyperphosphatemia.","oneSentence":"Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:57.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperphosphatemia in patients with chronic kidney disease on dialysis"}]},"trialDetails":[{"nctId":"NCT04485039","phase":"PHASE4","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","status":"COMPLETED","sponsor":"SIGA Technologies","startDate":"2022-06-08","conditions":"Smallpox","enrollment":44},{"nctId":"NCT00441545","phase":"PHASE3","title":"Head to Head Study Against Sevelamer Hydrochloride","status":"COMPLETED","sponsor":"Shire","startDate":"2007-01-05","conditions":"Chronic Kidney Disease, Stage 5","enrollment":182},{"nctId":"NCT00880750","phase":"PHASE1","title":"Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults","status":"COMPLETED","sponsor":"Shire","startDate":"2009-01-28","conditions":"End Stage Renal Disease","enrollment":72},{"nctId":"NCT01128179","phase":"PHASE2","title":"Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD","status":"COMPLETED","sponsor":"Shire","startDate":"2010-12-06","conditions":"Chronic Kidney Disease","enrollment":35},{"nctId":"NCT00660530","phase":"PHASE2","title":"Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2008-01","conditions":"Hyperphosphatemia, Kidney Disease","enrollment":11},{"nctId":"NCT01419327","phase":"","title":"Fosrenol Post-marketing Surveillance for Hemodialysis in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03-23","conditions":"Hyperphosphatemia","enrollment":3267},{"nctId":"NCT01412398","phase":"","title":"Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-04-07","conditions":"Hyperphosphatemia","enrollment":446},{"nctId":"NCT03074058","phase":"PHASE1","title":"Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-10","conditions":"Clinical Pharmacology","enrollment":20},{"nctId":"NCT01053676","phase":"PHASE1","title":"Bioequivalence Study of BAY77-1931 Granule","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-01","conditions":"Hyperphosphatemia","enrollment":59},{"nctId":"NCT00841126","phase":"PHASE3","title":"Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate","status":"TERMINATED","sponsor":"Ineos Healthcare Limited","startDate":"2009-07","conditions":"Chronic Kidney Failure","enrollment":657}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BODY TEMPERATURE DECREASED"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CONSTIPATION"},{"count":1,"reaction":"CONTUSION"},{"count":1,"reaction":"DIALYSIS"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"EOSINOPHILIA"},{"count":1,"reaction":"HAEMORRHAGE SUBCUTANEOUS"},{"count":1,"reaction":"HEPATIC NEOPLASM MALIGNANT"},{"count":1,"reaction":"HEPATITIS CHOLESTATIC"}],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fosrenol"],"phase":"marketed","status":"active","brandName":"Lanthanum Carbonate Chewable Tablet","genericName":"Lanthanum Carbonate Chewable Tablet","companyName":"SIGA Technologies","companyId":"siga-technologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lanthanum carbonate binds phosphate in the gastrointestinal tract, reducing serum phosphate levels in patients with chronic kidney disease. Used for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Hyperphosphatemia in patients with chronic kidney disease not on dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}